On May 30, 2026, the 2nd Summit Forum on Mass Spectrometry‑Independent Proteomic Technologies and Precision Medicine and the 1st Symposium on the Human Functional Antibodyome were held at the Systems Biomedicine Research Building, Minhang Campus, Shanghai Jiao Tong University. The conference was hosted by Shanghai Jiao Tong University and co-organized by the National Center for Protein Sciences (Beijing), the Chinese Human Proteome Organization (CNHUPO), and the Systems Biomedicine Committee of the Chinese Society of Biotechnology (CSBT). The forum focused on frontier innovations in mass spectrometry‑independent proteomics and their translational applications in precision medicine.
Meeting Report | The 2nd Summit Forum on Mass Spectrometry-Independent Proteomic Technologies and Precision Medicine & The 1st Symposium on the Human Functional Antibodyome Held at Shanghai Jiao Tong University
The conference focused on next-generation protein detection and profiling platforms, including protein microarrays, aptamers, PhIP‑seq, nucleic acid encoding, NULISA, and exosome proximity encoding. Key discussions centered on the application potential of these technologies in large‑scale population cohorts, high‑throughput biomarker screening, early disease detection, precise subtyping, therapeutic response prediction, and long‑term monitoring. Participating experts shared recent advances from the perspectives of fundamental technology, clinical needs, data analysis, and industrial translation, highlighting a clear trend in proteomics shifting from a “discovery‑driven” to an “application‑oriented” paradigm.
The presentations covered multiple representative directions. Professor Zhu Heng introduced next‑generation single‑cell proteomics and epigenetic proteomics, demonstrating the value of protein microarray platforms in single‑cell resolution and protein functional characterization. Researcher Wu Qin focused on the chemical dissection and precise intervention of membrane proteins, presenting the application of nucleic acid aptamers, nucleic acid‑encoded probes, and sequencing technologies in *in situ* membrane protein profiling and tumor subtyping research. Professor Qian Kun, from the perspective of “omics engineering,” emphasized the need to establish high‑performance detection and regulatory tools tailored to different molecular systems, and to design both mass spectrometry and non‑mass spectrometry platforms according to specific application scenarios. Professor Hu Fanlei, based on his work in rheumatic and immune diseases, introduced the use of multiple technologies including PhIP‑seq for discovering autoantibody biomarkers and advancing diagnostic translation.
In terms of precision medicine applications, Researcher You Jia presented biomedical big data‑driven research on disease prediction and risk stratification, demonstrating the potential of proteomics in population cohorts and early identification of neurodegenerative diseases. Professor Sheng Jianpeng shared translational medicine research based on the NULISA ultra‑sensitive protein detection technology, highlighting the importance of low‑abundance protein detection and longitudinal monitoring for evaluating treatment response. Dr. Wu Di introduced the application of proximity encoding technology in high‑precision proteomics, particularly inferring exosome origin and functional status through single‑exosome protein combination analysis. Researcher Yu Xiaobo reported on the progress of the non‑mass spectrometry proteomics technology project and related work on the Human Functional Antibodyome, emphasizing the prospects of antibody big data, automated chip platforms, and AI analysis tools in early disease screening, subtyping, and health management.